Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions
The addition of the anti-CD38 monoclonal antibody isatuximab to standard therapies is transforming the care of patients with newly diagnosed multiple myeloma (NDMM), as previously seen in the relapsed/refractory setting. This is particularly important for patients with NDMM as early treatment with e...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
23 Jul 2025
|
| In: |
Expert opinion on investigational drugs
Year: 2025, Jahrgang: 34, Heft: 7-8, Pages: 571-589 |
| ISSN: | 1744-7658 |
| DOI: | 10.1080/13543784.2025.2532446 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1080/13543784.2025.2532446
|
| Verfasserangaben: | Paul G. Richardson, Elisabeth K. O’Donnell, Peter O’Gorman, Lisa B. Leypoldt, Jacob Laubach, Francesca Gay, Xavier Leleu, Thierry Facon, Philippe Moreau, Meletios A. Dimopoulos, Hartmut Goldschmidt, Elias K. Mai, Michele Cavo, Katja C. Weisel, Jesus G. Berdeja, Robert Z. Orlowski, Meral Beksaç, Aurore Perrot, Joseph Mikhael and Thomas Martin |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1942698461 | ||
| 003 | DE-627 | ||
| 005 | 20251127120107.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251127s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13543784.2025.2532446 |2 doi | |
| 035 | |a (DE-627)1942698461 | ||
| 035 | |a (DE-599)KXP1942698461 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Richardson, Paul G. |e VerfasserIn |0 (DE-588)1073660222 |0 (DE-627)829311114 |0 (DE-576)435237594 |4 aut | |
| 245 | 1 | 0 | |a Isatuximab for the treatment of multiple myeloma |b current clinical advances and future directions |c Paul G. Richardson, Elisabeth K. O’Donnell, Peter O’Gorman, Lisa B. Leypoldt, Jacob Laubach, Francesca Gay, Xavier Leleu, Thierry Facon, Philippe Moreau, Meletios A. Dimopoulos, Hartmut Goldschmidt, Elias K. Mai, Michele Cavo, Katja C. Weisel, Jesus G. Berdeja, Robert Z. Orlowski, Meral Beksaç, Aurore Perrot, Joseph Mikhael and Thomas Martin |
| 264 | 1 | |c 23 Jul 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 19 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 23. Juli 2025 | ||
| 500 | |a Gesehen am 27.11.2025 | ||
| 520 | |a The addition of the anti-CD38 monoclonal antibody isatuximab to standard therapies is transforming the care of patients with newly diagnosed multiple myeloma (NDMM), as previously seen in the relapsed/refractory setting. This is particularly important for patients with NDMM as early treatment with effective, well tolerated therapies may ensure better clinical outcomes. Here, we examine recent results from pivotal Phase 3 and 2 clinical trials that demonstrate efficacy and safety of isatuximab across multiple combinations, for both transplant-ineligible and transplant-eligible NDMM patients. We then evaluate long-term outcomes from the IKEMA and ICARIA-MM trials as well as real-world evidence emerging from analyses conducted in patients with relapsed/refractory MM (RRMM). Further, we address current approaches to optimize treatment with isatuximab-based combinations involving changes in bortezomib or dexamethasone dosing. Lastly, we review current findings with new administration modalities developed to optimize delivery of isatuximab in the clinic. Supported by multiple lines of high-level evidence, isatuximab in combination with standard-of-care backbone therapies produces triplet or quadruplet regimens with enhanced efficacy and consistent safety for the treatment of patients with NDMM and RRMM. | ||
| 650 | 4 | |a CD38 | |
| 650 | 4 | |a isatuximab | |
| 650 | 4 | |a monoclonal antibody | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a newly diagnosed | |
| 650 | 4 | |a relapsed/refractory | |
| 700 | 1 | |a O’Donnell, Elisabeth K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a O’Gorman, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Leypoldt, Lisa B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Laubach, Jacob |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gay, Francesca |e VerfasserIn |4 aut | |
| 700 | 1 | |a Leleu, Xavier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Facon, Thierry |e VerfasserIn |4 aut | |
| 700 | 1 | |a Moreau, Philippe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dimopoulos, Meletios A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Mai, Elias K. |d 1985- |e VerfasserIn |0 (DE-588)1049182545 |0 (DE-627)781300274 |0 (DE-576)403130999 |4 aut | |
| 700 | 1 | |a Cavo, Michele |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weisel, Katja C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Berdeja, Jesus G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Orlowski, Robert Z. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Beksaç, Meral |e VerfasserIn |4 aut | |
| 700 | 1 | |a Perrot, Aurore |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mikhael, Joseph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Martin, Thomas |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d Abingdon, Oxon : Routledge, Taylor & Francis, 1994 |g 34(2025), 7-8, Seite 571-589 |h Online-Ressource |w (DE-627)324741855 |w (DE-600)2030114-5 |w (DE-576)302969314 |x 1744-7658 |7 nnas |a Isatuximab for the treatment of multiple myeloma current clinical advances and future directions |
| 773 | 1 | 8 | |g volume:34 |g year:2025 |g number:7-8 |g pages:571-589 |g extent:19 |a Isatuximab for the treatment of multiple myeloma current clinical advances and future directions |
| 856 | 4 | 0 | |u https://doi.org/10.1080/13543784.2025.2532446 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251127 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1049182545 |a Mai, Elias K. |m 1049182545:Mai, Elias K. |d 910000 |d 910100 |d 50000 |e 910000PM1049182545 |e 910100PM1049182545 |e 50000PM1049182545 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 12 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 11 | ||
| 999 | |a KXP-PPN1942698461 |e 4814793308 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"23 Jul 2025","dateIssuedKey":"2025"}],"note":["Online veröffentlicht: 23. Juli 2025","Gesehen am 27.11.2025"],"title":[{"title_sort":"Isatuximab for the treatment of multiple myeloma","subtitle":"current clinical advances and future directions","title":"Isatuximab for the treatment of multiple myeloma"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1942698461","relHost":[{"language":["eng"],"titleAlt":[{"title":"EOID"}],"part":{"issue":"7-8","text":"34(2025), 7-8, Seite 571-589","year":"2025","pages":"571-589","volume":"34","extent":"19"},"title":[{"subtitle":"EOID","title_sort":"Expert opinion on investigational drugs","title":"Expert opinion on investigational drugs"}],"origin":[{"publisherPlace":"Abingdon, Oxon ; London [u.a.]","dateIssuedDisp":"1994-","dateIssuedKey":"1994","publisher":"Routledge, Taylor & Francis ; Informa Healthcare"}],"note":["Gesehen am 03.09.15"],"pubHistory":["Nachgewiesen 3.1994 -"],"disp":"Isatuximab for the treatment of multiple myeloma current clinical advances and future directionsExpert opinion on investigational drugs","type":{"media":"Online-Ressource","bibl":"periodical"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"324741855","id":{"issn":["1744-7658"],"zdb":["2030114-5"],"eki":["324741855"]}}],"name":{"displayForm":["Paul G. Richardson, Elisabeth K. O’Donnell, Peter O’Gorman, Lisa B. Leypoldt, Jacob Laubach, Francesca Gay, Xavier Leleu, Thierry Facon, Philippe Moreau, Meletios A. Dimopoulos, Hartmut Goldschmidt, Elias K. Mai, Michele Cavo, Katja C. Weisel, Jesus G. Berdeja, Robert Z. Orlowski, Meral Beksaç, Aurore Perrot, Joseph Mikhael and Thomas Martin"]},"physDesc":[{"noteIll":"Illustrationen","extent":"19 S."}],"id":{"eki":["1942698461"],"doi":["10.1080/13543784.2025.2532446"]},"person":[{"display":"Richardson, Paul G.","family":"Richardson","role":"aut","given":"Paul G."},{"given":"Elisabeth K.","role":"aut","family":"O’Donnell","display":"O’Donnell, Elisabeth K."},{"family":"O’Gorman","display":"O’Gorman, Peter","given":"Peter","role":"aut"},{"given":"Lisa B.","role":"aut","family":"Leypoldt","display":"Leypoldt, Lisa B."},{"family":"Laubach","display":"Laubach, Jacob","role":"aut","given":"Jacob"},{"given":"Francesca","role":"aut","family":"Gay","display":"Gay, Francesca"},{"given":"Xavier","role":"aut","display":"Leleu, Xavier","family":"Leleu"},{"given":"Thierry","role":"aut","display":"Facon, Thierry","family":"Facon"},{"family":"Moreau","display":"Moreau, Philippe","given":"Philippe","role":"aut"},{"display":"Dimopoulos, Meletios A.","family":"Dimopoulos","role":"aut","given":"Meletios A."},{"given":"Hartmut","role":"aut","family":"Goldschmidt","display":"Goldschmidt, Hartmut"},{"role":"aut","given":"Elias K.","family":"Mai","display":"Mai, Elias K."},{"display":"Cavo, Michele","family":"Cavo","role":"aut","given":"Michele"},{"role":"aut","given":"Katja C.","family":"Weisel","display":"Weisel, Katja C."},{"family":"Berdeja","display":"Berdeja, Jesus G.","given":"Jesus G.","role":"aut"},{"display":"Orlowski, Robert Z.","family":"Orlowski","given":"Robert Z.","role":"aut"},{"given":"Meral","role":"aut","family":"Beksaç","display":"Beksaç, Meral"},{"family":"Perrot","display":"Perrot, Aurore","role":"aut","given":"Aurore"},{"display":"Mikhael, Joseph","family":"Mikhael","role":"aut","given":"Joseph"},{"role":"aut","given":"Thomas","family":"Martin","display":"Martin, Thomas"}],"language":["eng"]} | ||
| SRT | |a RICHARDSONISATUXIMAB2320 | ||